Merrimack Pharmaceuticals Inc (MACK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Sales | 0 | 0 | 0 | 0 | 102,756 |
| Gross Profit | N/A | N/A | N/A | N/A | 102,756 |
| Operating Expenses | 65,575 | 95,766 | 147,327 | 145,081 | 169,012 |
| Operating Income | -65,575 | -95,766 | -147,327 | -145,081 | -66,256 |
| Interest Expense | 956 | 34,650 | 22,449 | 18,769 | 18,230 |
| Other Income | -1,931 | 12,013 | 268 | 1,016 | 927 |
| Pre-tax Income | -68,462 | -118,403 | -169,508 | -162,834 | -83,559 |
| Income Tax | -7,695 | -42,399 | -13,224 | -11,215 | N/A |
| Net Income Continuous | -60,767 | -76,004 | -156,284 | -151,619 | -83,559 |
| Net Income Discontinuous | 20,261 | 546,872 | 2,766 | 3,832 | N/A |
| Minority Interests | N/A | -1,160 | -1,778 | 170 | -268 |
| Net Income | $-40,506 | $472,028 | $-151,740 | $-147,957 | $-83,291 |
| EPS Basic Total Ops | -3.03 | 35.67 | -12.11 | -13.29 | -8.00 |
| EPS Basic Continuous Ops | -4.55 | -5.66 | -12.33 | -13.63 | -8.00 |
| EPS Basic Discontinuous Ops | 1.52 | 41.33 | 0.22 | 0.34 | N/A |
| EPS Diluted Total Ops | -3.03 | 35.67 | -12.11 | -13.29 | -8.00 |
| EPS Diluted Continuous Ops | -4.55 | -5.66 | -12.33 | -13.63 | -8.00 |
| EPS Diluted Discontinuous Ops | 1.52 | 41.33 | 0.22 | 0.34 | N/A |
| EPS Diluted Before Non-Recurring Items | -4.55 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-62,152 | $-90,545 | $-142,432 | $-141,831 | $-63,033 |